Combined laser and bevacizumab in ROP treatment

Comparing the effect of near confluent laser versus combination of less dense laser and bevacizumab on prethreshold Retinopathy of prematurity (ROP) type 1 zone 2: Randomized clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201120049450N1

Enrollment

Registered

2021-12-27

Start date

2021-11-04

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of prematurity. Retinopathy of prematurity, unspecified, unspecified eye

Interventions

Intervention 1: Intervention group: combined less dense laser and intravitreal Bevacizumab(dosage: 0.625micro). This combination treatment is performed in Khalili's operating room with prior reservati

Eligibility

Sex/Gender

All

Age

1 Months to 4 Months

Inclusion criteria

Inclusion criteria: Retinopathy of prematurity Type 1 prethreshold location: Zone 2 of retina (from posterior circle to nasal ora serrata)

Exclusion criteria

Exclusion criteria: elavated demarcation ridge vitreous hemorrhage threshold zone 1 neovascularization of iris

Design outcomes

Primary

Measure	Time frame
Regression and progression of vascularization. Timepoint: Monthly up to 6 months. Method of measurement: Fundus examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Namvar

Shiraz University of Medical Sciences

Namvar.e@gmail.com+98 71 3629 1779

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 11, 2026